Gillinder Bedi

Associate Professor; Head of Substance Use Research at Orygen and Principal Research Fellow at the Centre for Youth Mental Health, University of Melbourne

Data updated

Papers

7 publications

Trials

0 clinical trials

Links

Research Footprint

Gillinder Bedi appears in 7 tracked papers (2010–2025), most studied alongside MDMA, Placebo and Psilocybin, across Interpersonal Functioning & Social Connectedness, PTSD and Substance Use Disorders (SUD).

Most-cited paper: Is Ecstasy an “Empathogen”? Effects of ±3,4-Methylenedioxymethamphetamine on Prosocial Feelings and Identification of Emotional States in Others (245 citations).

Frequent co-authors: Harriet de Wit, Suresh Muthukumaraswamy and Matthew Baggot.

Background & Research

Gillinder Bedi is a clinical psychologist and academic researcher based at Orygen and the University of Melbourne. Her earlier training and postdoctoral work focused on the acute effects of MDMA/ecstasy in humans, including cognition, mood, and social behavior, and she has also held a faculty position at Columbia University Medical Center/New York State Psychiatric Institute. Her current research centers on substance use, experimental medicine, and the methodology, safety, and ethics of psychedelic-assisted psychotherapy research.

Key Impact

Gillinder Bedi is a leading human psychopharmacology and psychedelic/MDMA researcher whose work has helped define the acute social and behavioral effects of MDMA and inform the safety and ethics of psychedelic-assisted therapy.

7

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

6 collaborators· click a node to visit their profile

Full network →

Affiliations

Institutions, companies, and organisations Gillinder Bedi is associated with.